Clinical development of panobinostat in classical Hodgkin's lymphoma. - Wikidata - awgldk - TriplyDB

Clinical development of panobinostat in classical Hodgkin's lymphoma.

Clinical development of panobinostat in classical Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q37888710

about

Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation.Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives.Lymphangiogenesis in Classical Hodgkin Lymphoma - Preliminary Study with Clinicopathological Correlations A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.

P2860

Q33400014-CB825FB8-E073-4FB9-BA27-EF25C8EDDA89 Q33405096-DAC1AE75-B982-4232-A3B0-0F39CB9D2DF1 Q33410761-BA4E59F7-8E94-4378-AFE4-13C24CB1E59F Q38012499-5C1CC3D4-7728-47EA-BBC5-C017C76178C6 Q38844615-A0FB4DC3-439B-4CB1-8824-2174E7C989FE Q41873357-4E2CB46D-989E-4B8F-A5A2-3C3B21E0E649 Q42684972-DDEFBE5E-1781-432A-A72B-31779E76D371

P2860

Clinical development of panobinostat in classical Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q37888710

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical development of panobinostat in classical Hodgkin's lymphoma.

@en

Clinical development of panobinostat in classical Hodgkin's lymphoma.

@nl

type

label

Clinical development of panobinostat in classical Hodgkin's lymphoma.

@en

Clinical development of panobinostat in classical Hodgkin's lymphoma.

@nl

prefLabel

Clinical development of panobinostat in classical Hodgkin's lymphoma.

@en

Clinical development of panobinostat in classical Hodgkin's lymphoma.

@nl

P1433

Q37888710-CBF98B8E-A3CB-42FD-84DA-7E5BBD9EAC8B

P1476

Q37888710-9F1D2DF6-9FFF-48A7-8454-B4797E0974A7

P2093

Q37888710-A0A591CC-2E75-4E14-9D3E-D7B26F390324

Q37888710-BD4A5711-ACB8-4B09-A4B9-93856E87EAD8

Q37888710-C849A647-5F0F-4A0C-990E-BC9089760807

P2860

Q37888710-03C9B3EE-7FA4-404F-B2C3-915542EF52FB

Q37888710-0A0B805E-4395-497D-AE8F-E9E924D49C6B

Q37888710-221463AB-CE5C-405D-803C-33B0584B5490

Q37888710-2419D877-5C2F-4420-A949-B2295A5914CC

Q37888710-4D075B3C-148C-4FA2-9EAF-A6B562FA813D

Q37888710-4E158A25-E634-4223-91A3-3DF9165C7F6E

Q37888710-54238532-6CD9-46FB-AC6D-759523BA14CF

Q37888710-56939926-604D-41FF-B8E1-550EEB51E02B

Q37888710-636673DB-D0A3-4322-8494-EC89C6B35F4C

Q37888710-77C01D05-CE78-45BD-A799-F52046D301D0

P304

Q37888710-F7C4F99C-97F2-4C76-913C-1388D4AB60FB

P31

Q37888710-EF320EBB-1148-46DB-B03E-10E5F6B80A61

P356

Q37888710-40E5DB0E-F5FB-419F-B14E-91F45FCF64AB

P433

Q37888710-CF5A5D72-9283-41E7-BEE2-0D4B2AAC32CC

P478

Q37888710-16A51888-06F4-4261-9B2B-AEA100FC1331

P577

Q37888710-F73C365D-9A0D-461C-9E2F-3A92C473D449

P698

Q37888710-3E5D8202-7CE4-4AFB-BD9E-904BB82D62AE

P356

P1433

Expert Review of Hematology

P1476

Clinical development of panobinostat in classical Hodgkin's lymphoma.

@en

P2093

Amanda Copeland

http://www.w3.org/2001/XMLSchema#string

Anas Younes

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Oki

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Epigenetics in cancer

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Anticancer activities of histone deacetylase inhibitors

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.

HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.

Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines.

P304

245-252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/EHM.11.24

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21668391

http://www.w3.org/2001/XMLSchema#string